INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,993,063 | -13.5% | 441,410 | +5.1% | 0.02% | -10.0% |
| Q2 2023 | $26,582,137 | +43.2% | 419,806 | +22.3% | 0.02% | +33.3% |
| Q1 2023 | $18,559,513 | +3.3% | 343,377 | +1.1% | 0.02% | 0.0% |
| Q4 2022 | $17,974,912 | +21.6% | 339,662 | +6.9% | 0.02% | +15.4% |
| Q3 2022 | $14,787,000 | -18.9% | 317,795 | -0.5% | 0.01% | -13.3% |
| Q2 2022 | $18,226,000 | +56.2% | 319,299 | +67.5% | 0.02% | +87.5% |
| Q1 2022 | $11,666,000 | +2242.6% | 190,663 | +1905.5% | 0.01% | – |
| Q4 2021 | $498,000 | +55.1% | 9,507 | +10.3% | 0.00% | – |
| Q3 2021 | $321,000 | -0.6% | 8,621 | +8.9% | 0.00% | – |
| Q2 2021 | $323,000 | -65.9% | 7,918 | -87.9% | 0.00% | -100.0% |
| Q4 2017 | $946,000 | -8.2% | 65,330 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $1,031,000 | -45.7% | 65,330 | +33.6% | 0.00% | -50.0% |
| Q2 2016 | $1,898,000 | – | 48,896 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |